Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, August 19, 2024

Patient enrollment begins in study of novel light therapy for Parkinson’s disease

 With your risk of Parkinson's post stroke, your competent doctor should figure out if this therapy could prevent Parkinsons.  At least, IF YOU HAVE A COMPETENT DOCTOR! DO YOU?

 

Parkinson’s Disease May Have Link to Stroke March 2017

 

The latest here:

Patient enrollment begins in study of novel light therapy for Parkinson’s disease 

The first 100 patients have been enrolled in a clinical trial investigating a novel light therapy device intended to treat individuals with Parkinson’s disease, according to the manufacturer.

In a company press release, PhotoPharmics said it will examine its Celeste device, which was previously granted FDA breakthrough designation, in the Light for PD study, which is expected to enroll 300 people.

Parkinson's disease
A Utah-based company specializing in neurodegenerative disease phototherapy announced that enrollment began in a clinical trial investigating a light therapy device for Parkinson’s disease. Image: Adobe Stock

The randomized, double-blind, placebo-controlled study will be conducted by the University of Rochester’s Center for Health + Technology.

Celeste passively delivers specific wavelengths of light to the eye with the goal of improving function and quality of life for those affected by Parkinson’s, according to the release.

Enrollees are expected to use the Celeste device within their own homes for 1 hour per day when doing activities like reading, eating or watching TV.

The study’s primary endpoints are improvements in overall quality of life, motor function, sleep quality, mood and cognition, evaluated by clinical scales and patient-reported outcomes.

“We are thrilled to reach this important milestone,” PhotoPharmics CEO Kent Savage said in the release. “We are grateful for the team at the University of Rochester’s Center for Health + Technology (CHeT) and the movement disorder neurologists across the country who are enrolling and caring for trial participants. We believe our passive and non-invasive specialized phototherapy device will provide substantial benefits to those affected by this debilitating disease.”

Sources/Disclosures

Collapse

Source:

Press Release

No comments:

Post a Comment